More info
Active ingredients
Ossein hydroxyapatite compound
Release form
Pills
Composition
The 1 tablet of the drug in the Ossein-hydroxyapatite complex contains 291 mg of ossein (non-collagen peptides and proteins - 75 mg, collagen proteins - 216 mg) and 444 mg of hydroxyapatite (calcium - 178 mg, phosphorus - 82 mg). Coat composition: hypromellose, titanium dioxide, macrogol , talc, iron oxide yellow
Pharmacological effect
Osteogenone is an ossein-hydroxyapatite complex that affects phosphorus-calcium metabolism. The drug has a double effect on bone metabolism in osteoporosis: a stimulating effect on osteoblasts (due to the organic, ossein component) and an inhibitory effect on osteoclasts (due to inorganic calcium in the composition of hydroxyapatite). The organic component of Osteogenone contains a number of proteins that are normally synthesized by bone tissue cells: transforming beta-growth factor, insulin-like growth factors, osteocalcin, which activate the formation of bone tissue and inhibit its resorption.
Pharmacokinetics
Calcium, which is part of Osteogenone, is contained in the form of hydroxyapatite (in relation to phosphorus 2: 1), which contributes to its more complete absorption from the digestive tract. After taking the drug inside, there is a good and uniform absorption of calcium, which is part of it.
Indications
Prevention and treatment of primary osteoporosis of various etiologies (premenopausal, menopausal, senile); - Prevention and treatment of secondary osteoporosis of various etiologies (due to rheumatoid arthritis, liver and kidney diseases, hyperthyroidism, hyperparathyroidism, imperfect osteogenesis, the use of GCS, hepatitis, and hepatopathology. osteopenia and disorders of phosphorus-calcium metabolism (including during pregnancy and during breastfeeding); - acceleration of healing of bone fractures
Contraindications
Severe renal failure; - hemodialysis; - severe hypercalciuria; - childhood; - hypersensitivity to the components of the drug
Precautionary measures
In studies of the drug was not detected teratogenic effects on the fetus.However, the described drug should not be used during pregnancy without first consulting with a specialist. Patients predisposed to urolithiasis require individual correction of the dosage and regimen of the drug. Patients with impaired renal function should avoid prolonged use of the drug in large doses. For patients suffering from arterial hypertension, let's say osteogenone, as the drug contains a very small amount of sodium chloride. When Osteogenone is taken with eduet remembered that the active drug slows the absorption of drugs containing iron, as well as tetracyclines, so between their methods should do interval of at least 4 hours.
Use during pregnancy and lactation
Osteogenone can be used during pregnancy and during breastfeeding according to indications after consulting a doctor
Dosage and administration
Adults with osteoporosis are recommended to take orally for 2-4 tab. 2 times / day; according to other indications - 1-2 pills / day. The duration of treatment is determined by the patient's condition
Side effects
In very rare cases (<1/1 000 000) the following are possible: allergic reactions; with prolonged use - hypercalcemia, hypercalciuria
Overdose
Currently, the cases of drug overdose Osteogenon were reported
Interaction with other drugs
Osteogenone slows down the absorption of iron preparations, bisphosphonates and antibiotics of the tetracycline group, therefore, when used with these drugs, the time interval between taking them should be at least 4 hours. If Osteogenone is used with vitamin D or thiazide diuretics, the doctor should assess the risk of hypercalcemia due to the increase calcium resorption.
special instructions
In patients predisposed to urolithiasis, it may be necessary to adjust the dosage regimen of the drug, depending on laboratory parameters. In patients with impaired renal function, prolonged use of high doses of the drug should be avoided. The preparation contains only trace amounts of sodium chloride, therefore it is acceptable to use Osteogenon in patients with arterial hypertension